Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma

SIMPLE SUMMARY: The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rates. These agents are actively being investigated earlier in the sequence of therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Voorhees, Timothy J, Beaven, Anne W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601361/
https://www.ncbi.nlm.nih.gov/pubmed/33050054
http://dx.doi.org/10.3390/cancers12102887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601361/
https://www.ncbi.nlm.nih.gov/pubmed/33050054
http://dx.doi.org/10.3390/cancers12102887

Ejemplares similares